Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma

Neuroblastomas are tumors of peripheral sympathetic neurons and are the most common solid tumor in children. To determine the genetic basis for neuroblastoma, we performed whole-genome sequencing (6 cases), exome sequencing (16 cases), genome-wide rearrangement analyses (32 cases) and targeted analyses of specific genomic loci (40 cases) using massively parallel sequencing. On average, each tumor had 19 somatic alterations in coding genes (range of 3–70). Among genes not previously known to be involved in neuroblastoma, chromosomal deletions and sequence alterations of the chromatin-remodeling genes ARID1A and ARID1B were identified in 8 of 71 tumors (11%) and were associated with early treatment failure and decreased survival. Using tumor-specific structural alterations, we developed an approach to identify rearranged DNA fragments in sera, providing personalized biomarkers for minimal residual disease detection and monitoring. These results highlight the dysregulation of chromatin remodeling in pediatric tumorigenesis and provide new approaches for the management of patients with neuroblastoma.

[1]  A. Maitra,et al.  Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development , 2011, Science Translational Medicine.

[2]  D. Zwijnenburg,et al.  Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes , 2012, Nature.

[3]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[4]  Huanming Yang,et al.  Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder , 2011, Nature Genetics.

[5]  Jill P. Mesirov,et al.  MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.

[6]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[7]  Jinghui Zhang,et al.  Association of age at diagnosis and genetic mutations in patients with neuroblastoma. , 2012, JAMA.

[8]  Elaine R. Mardis,et al.  Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.

[9]  J. Maris.  Recent advances in neuroblastoma. , 2010, The New England journal of medicine.

[10]  Francisco M. De La Vega,et al.  Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing , 2010, Science Translational Medicine.

[11]  W. J. Kent,et al.  BLAT--the BLAST-like alignment tool. , 2002, Genome research.

[12]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[13]  R. Gibbs,et al.  Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 , 2011, Science.

[14]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[15]  P. Knoepfler,et al.  N-Myc Regulates Expression of Pluripotency Genes in Neuroblastoma Including lif, klf2, klf4, and lin28b , 2009, PloS one.

[16]  Matthew J. Betts,et al.  Dissecting the genomic complexity underlying medulloblastoma , 2012, Nature.

[17]  Nazneen Rahman,et al.  Integrative genomics identifies LMO1 as a neuroblastoma oncogene , 2011, Nature.

[18]  Michael A. Choti,et al.  DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.

[19]  Life Technologies,et al.  A map of human genome variation from population-scale sequencing , 2011 .

[20]  Bill Bynum,et al.  Lancet , 2015, The Lancet.

[21]  Gudrun Schleiermacher,et al.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.

[22]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[23]  Olivier Delattre,et al.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer , 1998, Nature.

[24]  Raul Rabadan,et al.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.

[25]  W. London,et al.  ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. , 2008, Cancer research.

[26]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[27]  W. Gerald,et al.  Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. , 2006, Cancer research.

[28]  Nazneen Rahman,et al.  Common variations in BARD1 influence susceptibility to high-risk neuroblastoma , 2009, Nature Genetics.

[29]  J. Trent,et al.  Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour , 1983, Nature.

[30]  A. Maitra,et al.  Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways , 2011, Proceedings of the National Academy of Sciences.

[31]  W. W. Nichols,et al.  Chromosomal deletion and retinoblastoma. , 1976, The New England journal of medicine.

[32]  K. Matthay,et al.  Neuroblastoma: Biology and staging , 2009, Current oncology reports.

[33]  G. Crabtree,et al.  Chromatin remodelling during development , 2010, Nature.

[34]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[35]  A. Puisieux,et al.  Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. , 2002, Cancer research.

[36]  L. Ries,et al.  Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. , 1999 .

[37]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[38]  Hugo Y. K. Lam,et al.  Performance comparison of exome DNA sequencing technologies , 2011, Nature Biotechnology.

[39]  Keith A. Boroevich,et al.  Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators , 2012, Nature Genetics.

[40]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[41]  S. Diskin,et al.  Genetics and genomics of neuroblastoma. , 2010, Cancer treatment and research.

[42]  N. Carter,et al.  Small regions of overlapping deletions on 6q26 in human astrocytic tumours identified using chromosome 6 tile path array-CGH , 2006, Oncogene.

[43]  R. Seeger,et al.  Gene amplification in human neuroblastomas: basic mechanisms and clinical implications. , 1986, Cancer genetics and cytogenetics.

[44]  Yuchen Jiao,et al.  Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma , 2011, Science.

[45]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[46]  P. A. Futreal,et al.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.

[47]  P. Dallas,et al.  Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. , 2004, The Biochemical journal.

[48]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[49]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[50]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[51]  Zev A. Binder,et al.  The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.

[52]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[53]  S. Ogawa,et al.  Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.